NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 727-732

  Leander, Karin ^a   Gigante, Bruna ^a,b   Silveira, Angela ^a   Vikström, Max ^a   Hamsten, Anders ^a,b   Högberg, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AKT1; Case control studies; Epidemiology; Myocardial infarction; Nicotinamide phosphoribosyltransferase; Polymorphisms, single nucleotide

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; AGED; AKT1 GENE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMPT GENE; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84857644434     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.002     Document Type: Article

References (40)

1. Garten A., Petzold S., Korner A., Imai S., Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009, 20:130-138.
2. Imai S. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res 2010, 62:42-47.
3. Hsu C.P., Oka S., Shao D., Hariharan N., Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res 2009, 105:481-491.
4. Ramsey K.M., Yoshino J., Brace C.S., et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 2009, 324:651-654.
5. Nakahata Y., Sahar S., Astarita G., Kaluzova M., Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 2009, 324:654-657.
6. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009, 71:202-207.
7. Wang L.S., Yan J.J., Tang N.P., et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep 2011, 38:819-825.
8. Dahl T.B., Yndestad A., Skjelland M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
9. Dahl T., Ranheim T., Holm S., Berge R., Aukrust P., Halvorsen B. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur J Clin Invest 2011, 41:1098-1104.
10. Lim S.Y., Davidson S.M., Paramanathan A.J., Smith C.C., Yellon D.M., Hausenloy D.J. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008, 12:1395-1403.
11. van der Veer E., Ho C., O'Neil C., et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 2007, 282:10841-10845.
12. Lovren F., Pan Y., Shukla P.C., et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009, 296:E1440-E1449.
13. Yamawaki H., Hara N., Okada M., Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009, 383:503-508.
14. Malmlof M., Roudier E., Hogberg J., Stenius U. MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. Mdm2 is activated in response to inhibited Akt signaling. J Biol Chem 2007, 282:2288-2296.
15. Yuan X.M., Osman E., Miah S., et al. p53 expression in human carotid atheroma is significantly related to plaque instability and clinical manifestations. Atherosclerosis 2010, 210:392-399.
16. Nadtochiy S.M., Redman E., Rahman I., Brookes P.S. Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. Cardiovasc Res 2011, 89:643-649.
17. Bailey S.D., Loredo-Osti J.C., Lepage P., et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006, 55:2896-2902.
18. Zhang Y.Y., Gottardo L., Thompson R., et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006, 14:2119-2126.
19. Bottcher Y., Teupser D., Enigk B., et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006, 91:2725-2731.
20. Miyamoto S., Rubio M., Sussman M.A. Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc Res 2009, 82:272-285.
21. Smith C.C., Yellon D.M. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011, 129:206-219.
22. Camper-Kirby D., Welch S., Walker A., et al. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 2001, 88:1020-1027.
23. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
24. Harris S.L., Gil G., Robins H., et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A 2005, 102:16297-16302.
25. Wang M., Crisostomo P.R., Markel T., Wang Y., Lillemoe K.D., Meldrum D.R. Estrogen receptor beta mediates acute myocardial protection following ischemia. Surgery 2008, 144:233-238.
26. Patten R.D., Pourati I., Aronovitz M.J., et al. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004, 95:692-699.
27. Deschamps A.M., Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 2009, 297:H1806-H1813.
28. Wang M., Wang Y., Weil B., et al. Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 2009, 296:R972-R978.
29. Wang F., He Q., Sun Y., Dai X., Yang X.P. Female adult mouse cardiomyocytes are protected against oxidative stress. Hypertension 2010, 55:1172-1178.
30. Revollo J.R., Korner A., Mills K.F., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
31. Reuterwall C., Hallqvist J., Ahlbom A., et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. J Intern Med 1999, 246:161-174.
32. Samnegard A., Silveira A., Lundman P., et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005, 258:411-419.
33. Vermylen C., De Vreker R.A., Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 1963, 8:418-424.
34. Cheng Z., Tseng Y., White M.F. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 2010, 21:589-598.
35. Benigni A., Corna D., Zoja C., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009, 119:524-530.
36. Costford S.R., Bajpeyi S., Pasarica M., et al. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab 2010, 298:E117-E126.
37. Brandt K.J., Carpintero R., Gruaz L., Molnarfi N., Burger D. A novel MEK2/PI3Kdelta pathway controls the expression of IL-1 receptor antagonist in IFN-beta-activated human monocytes. J Leukoc Biol 2010, 88:1191-1200.
38. Zotova E., Lyrenas L., de Faire U., Morgenstern R., Gigante B., Bennet A.M. The myeloperoxidase gene and its influence on myocardial infarction in a Swedish population: protective role of the -129A allele in women. Coron Artery Dis 2009, 20:322-326.
39. Vitale C., Fini M., Speziale G., Chierchia S. Gender differences in the cardiovascular effects of sex hormones. Fundam Clin Pharmacol 2010, 24:675-685.
40. Incalcaterra E., Caruso M., Balistreri C.R., et al. Role of genetic polymorphisms in myocardial infarction at young age. Clin Hemorheol Microcirc 2010, 46:291-298.